Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Male or female, age 18 or older
Must have had a very recent stroke or transient ischemic attack ("mini stroke") that can be confirmed by the study doctor
Able to be assigned to a study group no later than 48 hours after the stroke occurred
Has an image of the brain that confirms that the stroke was not caused by hemorrhage or other reason that could explain symptoms
You may not be if
A suspicion by the study doctor that the transient ischemic attack or stroke was caused by a blood clot that formed in the heart; examples of this include history of an abnormal heart rhythm known as atrial fibrillation or a ventricular aneurysm or defect of the heart.
Any condition requiring treatment with an anticoagulant
History of intracranial hemorrhage ("bleeding in the brain")
Gastrointestinal ("stomach or intestinal") bleeding in the last 3 months that required treatment
Planned or anticipated invasive surgery or procedure during the study